⭐ Start off 2025 with a powerful boost to your portfolio: January’s freshest AI-picked stocksUnlock stocks

Two Indian companies indicted in US for importing ingredients used in opioid fentanyl

Published 01/06/2025, 04:49 PM
Updated 01/06/2025, 04:50 PM
© Reuters. FILE PHOTO: Fentanyl precursors are displayed at Reuters' office in New York City, U.S., July 10, 2024. REUTERS/Andrew Kelly/File Photo
FTNMX552010
-

By Jonathan Stempel

NEW YORK (Reuters) - Two Indian chemical companies have been indicted for allegedly importing ingredients for the highly addictive opioid fentanyl into the United States and Mexico, the U.S. Department of Justice said on Monday.

Athos Chemicals and Raxuter Chemicals, both based in Gujarat, were each charged in Brooklyn with distributing the ingredients and conspiring to distribute them.

Raxuter and senior executive Bhavesh Lathiya, 36, were also charged with smuggling, and introducing misbranded drugs into interstate commerce.

Lathiya was arrested on Saturday in New York and ordered detained pending trial, after prosecutors called him a flight risk and a substantial danger to the community.

"The Justice Department is targeting every link in fentanyl trafficking supply chains that span countries and continents and too often end in tragedy in the United States," U.S. Attorney General Merrick Garland said in a statement.

A federal public defender representing Lathiya declined to comment. Athos and Raxuter did not immediately respond to similar requests outside business hours.

Fentanyl is a synthetic opioid about 50 times more powerful than heroin and 100 times more powerful than morphine.

Opioids accounted for about 82,000 U.S. deaths in 2022, ten times the number in 1999, according to the U.S. Centers for Disease Control and Prevention.

Prosecutors said that since February 2024, the defendants supplied "precursor" chemicals they knew would be used to make fentanyl, and hid their efforts by mislabeling packages, falsifying customs forms, and making false declarations at border crossings.

One indictment said that in October 2024 video calls with an undercover agent posing as a fentanyl manufacturer, Lathiya agreed to sell 20 kilograms of the precursor chemical 1-boc-4-piperidone, and suggested mislabeling them as an antacid.

Lathiya did this after the agent told him his Mexico clients were "very happy with the quality of what you sent me," and with the "yield" from the resulting fentanyl, the indictment said.

© Reuters. FILE PHOTO: Fentanyl precursors are displayed at Reuters' office in New York City, U.S., July 10, 2024. REUTERS/Andrew Kelly/File Photo

The other indictment said Athos agreed last February to sell 100 kilograms of the same chemical to a known drug trafficker in Mexico who was making fentanyl in connection with a drug trafficking organization.

Lathiya faces up to 53 years in prison if convicted, the Justice Department said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.